AMGN240628C307500
- 5.30
- 0.000.00%
Amgen Newsroom
Study Links GLP-1 Drugs, Metformin to Lower Risk of Certain Cancers
Amgen Inc. (NASDAQ:AMGN) Shares Could Be 42% Below Their Intrinsic Value Estimate
Amgen (AMGN.US) has obtained commercial rights for Evolocumab in Asia and other areas and has applied for listing in China.
On July 3rd, Amgen (AMGN.US) announced that it has reached an agreement with CSL Vifor to acquire commercial rights to Evolocumab in Asia and the Americas, including mainland China.
S&P 500, Nasdaq 100 Climb To Record Highs As Data Fosters Rate Cut Optimism Ahead Of Fed Minutes; Gold, Bonds Rally: What's Driving Markets Wednesday?
The S&P 500 and Nasdaq 100 indices surged to new all-time highs on Thursday, as investors heightened their expectations for rate cuts following June's sharply lower-than-expected services sector activ
Express News | Amgen received commercialization rights for Avacopan in Asia and the Americas.
What the Options Market Tells Us About Amgen
Financial giants have made a conspicuous bearish move on Amgen. Our analysis of options history for Amgen (NASDAQ:AMGN) revealed 9 unusual trades.Delving into the details, we found 11% of traders were
Alvotech Says Study on Proposed Biosimilar to Prolia, Xgeva Meets Primary Endpoints
Alvotech (ALVO) said Tuesday a confirmatory study for AVT03, a proposed biosimilar to Amgen's (AMGN) denosumab sold as Prolia and Xgeva, met its primary endpoints. The study aims to show clinical simi
Amgen Unusual Options Activity
Whales with a lot of money to spend have taken a noticeably bearish stance on Amgen.Looking at options history for Amgen (NASDAQ:AMGN) we detected 10 trades.If we consider the specifics of each trade,
Watch Now: ETF Edge on Reshoring Trends, Weight Loss Drugs and More
Alnylam, Lilly, AstraZeneca Among Best Performing Pharmas, Biotechs in Q2
Rising Drug Costs Force a Third of Americans to Leave Prescriptions Unfilled: Report
Amgen Is Maintained at Buy by Argus Research
Amgen Is Maintained at Buy by Argus Research
Argus Research Maintains Buy on Amgen, Raises Price Target to $340
Argus Research analyst David Toung maintains Amgen (NASDAQ:AMGN) with a Buy and raises the price target from $300 to $340.
Amgen Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/27/2024 8.83% Argus Research $300 → $340 Maintains Buy 06/14/2024 6.27% RBC Capital $328 → $332 Maintai
Argus Research Maintains Amgen(AMGN.US) With Buy Rating, Raises Target Price to $340
Argus Research analyst Jasper Hellweg maintains $Amgen(AMGN.US)$ with a buy rating, and adjusts the target price from $310 to $340.According to TipRanks data, the analyst has a success rate of 60.5% a
Novo Nordisk, Eli Lilly Still Top 2 Pharma Stocks: Analyst
Novo Nordisk (NVO) and Eli Lilly (LLY) both made headlines recently with positive drug trial results for their respective GLP-1 weight-loss drugs, as well as their approval in China.
Novo-Nordisk's "miracle weight-loss drug" has been approved domestically, waiting to explode onto the multi-billion dollar market! How to capture this wave of "weight-loss fever"?
With the relentless competition among pharmaceutical research and development companies, the indications for GLP-1 are expected to continuously expand, and institutions are also constantly revising their expectations for the market size of weight-loss drugs.
US stocks dig gold | The two giants of weight-loss drugs have refreshed their heights! Novo Nordisk's weight-loss drug has been approved for sale in China; performance has ignited stock prices! Carnival Cruise Line soared nearly 9% after the results.
Medical global sectors are rebounding! Intuitive Surgical rose more than 3%, up more than 30% this year, with an average annual ROI of 24% over the past 15 years. Alnylam Pharmaceuticals rose nearly 8%, up more than 55% in the past four trading days, and positive phase 3 data for new drugs is still fermenting. Regeneron Pharmaceuticals rose nearly 1%, up more than 20% this year, with RBC Capital Markets analyst maintaining a target price of $1229 per share.
The Zacks Analyst Blog Highlights Chevron, Amgen, Philip Morris, Hurco and Perma-Pipe
Why Amgen (AMGN) Outpaced the Stock Market Today